806 related articles for article (PubMed ID: 26378418)
1. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
4. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
Niraula S; Le LW; Tannock IF
J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216
[TBL] [Abstract][Full Text] [Related]
6. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
Abrahamsson PA
Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
[TBL] [Abstract][Full Text] [Related]
7. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
Kratiras Z; Konstantinidis C; Skriapas K
Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
[TBL] [Abstract][Full Text] [Related]
8. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
9. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
10. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
Botrel TE; Clark O; dos Reis RB; Pompeo AC; Ferreira U; Sadi MV; Bretas FF
BMC Urol; 2014 Jan; 14():9. PubMed ID: 24460605
[TBL] [Abstract][Full Text] [Related]
11. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?
Shevach J; Sydes MR; Hussain M
Eur Urol Focus; 2019 Mar; 5(2):125-133. PubMed ID: 30803926
[TBL] [Abstract][Full Text] [Related]
12. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
[TBL] [Abstract][Full Text] [Related]
13. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
15. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.
Brungs D; Chen J; Masson P; Epstein RJ
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):105-11. PubMed ID: 24686773
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
18. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
20. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.
Klotz L
Curr Urol Rep; 2013 Jun; 14(3):159-67. PubMed ID: 23700095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
